ITRM vs NBIX · rev $390.0K vs P/E 45, rev $2.36B
Iterum Therapeutics PLC (ITRM) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Iterum Therapeutics PLC (ITRM) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ITRM revenue for 2025-09-30 was $390.0K. Net income was -$20.4M. ITRM currently screens at market cap $38.6M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ITRM currently screens at market cap $38.6M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ITRM and NBIX stock pages for the full models.
Not investment advice.